Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,360.79 +13.80 (+0.26%) Dow
38,868.04 +69.05 (+0.18%) Nasdaq
17,192.53 +59.40 (+0.35%) Bitcoin USD
69,499.27 -216.95 (-0.31%) CMC Crypto 200
1,442.09 -4.58 (-0.32%)
VRTX Sep 2024 490.000 call
- Business Wire
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
BOSTON, June 07, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 47th European Cystic Fibrosis Conference held June 5-8, 2024, in Glasgow, Scotland.
- GuruFocus.com
Insider Sale: EVP & CFO Charles F. Wagner Jr. Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
On June 3, 2024, Charles F. Wagner Jr., Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 3,250 shares of the company.
- GuruFocus.com
Insider Sale at Vertex Pharmaceuticals Inc (VRTX) by EVP, Chief Regulatory & Quality ...
On May 31, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 4,600 shares of the company.
